Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series

J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):451-454. doi: 10.1097/MPG.0000000000001788.

Abstract

The effect of ivacaftor in patients with cystic fibrosis (CF) with recurrent pancreatitis is unknown. We conducted a multicenter retrospective study of patients with CF taking ivacaftor who had a history of recurrent pancreatitis. During the first 3 months of therapy, only 1 of the 6 patients had an episode of pancreatitis, which was managed on an outpatient basis. Between 3 and 12 months on ivacaftor therapy, none of the patients had recurrence of pancreatitis or required hospitalization. The use of ivacaftor was associated with a reduced frequency and recurrence rate of pancreatitis in patients with CF.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aminophenols / therapeutic use*
  • Child
  • Child, Preschool
  • Chloride Channel Agonists / therapeutic use*
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pancreatitis, Chronic / etiology
  • Pancreatitis, Chronic / prevention & control*
  • Quinolones / therapeutic use*
  • Recurrence
  • Retrospective Studies
  • Secondary Prevention / methods*
  • Treatment Outcome
  • Young Adult

Substances

  • Aminophenols
  • Chloride Channel Agonists
  • Quinolones
  • ivacaftor